US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% NVDA $233.95 ▲+0.00% SNDK $1,719.99 ▲+0.00% SPCX $158.96 ▲+0.00% AMD $633.91 ▲+0.00% WDC $415.29 ▲+0.00% TSLA $370.59 ▲+0.00%
FinancialContent

Barinthus Biotherapeutics plc - American Depositary Shares (NQ:BRNS)

0.7401 UNCHANGED
Last Price Updated: 4:00 PM EDT, Sep 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Barinthus Biotherapeutics plc - American Depositary Shares

< Previous 1 2 3 Next >
News headline image
Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections
From Barinthus Biotherapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
BRNS Stock Earnings: Barinthus Biotherapeutics Beats EPS for Q4 2023 ↗
BRNS stock results show that Barinthus Biotherapeutics beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Barinthus Biotherapeutics: Q4 Earnings Insights ↗
 
Via Benzinga
News headline image
Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments
From Barinthus Biotherapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones
From Barinthus Biotherapeutics
Via GlobeNewswire
News headline image
New partnership aims to advance vaccine against MERS coronavirus
From Barinthus Biotherapeutics
Via GlobeNewswire
News headline image
Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD
From Barinthus Biotherapeutics
Via GlobeNewswire
News headline image
Barinthus Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Developments
From Barinthus Biotherapeutics
Via GlobeNewswire
News headline image
Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®
From Arbutus Biopharma Corporation
Via GlobeNewswire
< Previous 1 2 3 Next >